Cel Sci Corp
CVM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000725363
In the last 90 days, Cel Sci Corp insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $2.08M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Cel Sci Corp as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 112
- +9 vs. Q4 2021
- Shares held
- 13.5M
- −2.02M (−13.0%) vs. Q4 2021
- Total value
- $53.6M
- −$57.0M (−51.5%) vs. Q4 2021
- New holders
- 17
- 36 more added
- Sold out
- 8
- 33 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CVM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 40 | $2.08M |
| Q1 2026 | 39 | $2.43M |
| Q4 2025 | 40 | $3.90M |
| Q3 2025 | 35 | $8.01M |
| Q2 2025 | 28 | $1.10M |
| Q1 2025 | 53 | $1.73M |
| Q4 2024 | 62 | $2.75M |
| Q3 2024 | 66 | $6.32M |
| Q2 2024 | 67 | $7.22M |
| Q1 2024 | 78 | $14.5M |
| Q4 2023 | 73 | $17.9M |
| Q3 2023 | 66 | $6.79M |
| Q2 2023 | 61 | $13.2M |
| Q1 2023 | 64 | $13.1M |
| Q4 2022 | 76 | $13.8M |
| Q3 2022 | 78 | $20.0M |
| Q2 2022 | 85 | $34.5M |
| Q1 2022 | 112 | $53.6M |
| Q4 2021 | 103 | $110.5M |
| Q3 2021 | 110 | $177.3M |
| Q2 2021 | 117 | $121.1M |
| Q1 2021 | 115 | $208.5M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Cel Sci Corp; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Walleye Capital LLC | 277,278 | $1.09M | 0.03% | +216,113+353.3% | Added |
| Goldman Sachs Group Inc | 343,458 | $1.35M | 0.00% | +274,854+400.6% | Added |
| Northern Trust Corp | 352,469 | $1.39M | 0.00% | −18,787−5.1% | Reduced |
| Advisor Group Holdings, Inc. | 308,583 | $1.50M | 0.00% | +51,618+20.1% | Added |
| D.A. Davidson & Co. | 429,002 | $1.69M | 0.02% | +39,222+10.1% | Added |
| Two Sigma Investments, LP | 461,539 | $1.81M | 0.01% | +290,715+170.2% | Added |
| D. E. Shaw & Co., Inc. | 666,489 | $2.62M | 0.00% | +41,061+6.6% | Added |
| Geode Capital Management, LLC | 689,740 | $2.71M | 0.00% | +50,145+7.8% | Added |
| Renaissance Technologies LLC | 772,883 | $3.04M | 0.00% | +772,883 | New |
| State Street Corp | 980,339 | $3.85M | 0.00% | −2,388,659−70.9% | Reduced |
| Vanguard Group Inc | 2,066,788 | $8.12M | 0.00% | −11,094−0.5% | Reduced |
| BlackRock Inc. | 2,870,871 | $11.3M | 0.00% | −71,338−2.4% | Reduced |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −241,955−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −25,600−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −20,829−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −14,494−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −11,750−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −4,927−100.0% | Sold out |
| Chilton Capital Management LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Coastal Capital Group, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |